Home Market Outlook Today's Market Summary AI is poised to transform biopharma by reducing drug development time, cost, and risk, recalibrating the industry's core valuation drivers. AI-enabled assets show a dramatic improvement in risk-adjusted net present value, with my modeled example shifting from negative $238.5M to positive $356.5M. Major players like Eli Lilly (LLY) are leveraging proprietary AI infrastructure and partnerships, creating a competitive moat and new revenue verticals. Small and mid-cap biotechs can access advanced AI platforms as equalizers, but regulatory, model, and data risks remain material. Just_Super/iStock via Getty Images Overview If there is any industry that could benefit most from AI, I think it's biopharma ( XLV ) ( VHT ) ( IYH ).…